Activity Overview

Join us at this multidisciplinary, interactive, case-based meeting to enrich your knowledge of molecular biology, imaging, and current standard of care in resectable, unresectable, and metastatic pancreatic cancer. In this 1.5-day meeting, experts in the field will provide their insight on how they would treat their patients and encourage you to ask questions and discuss the challenges you face in your clinical practice.

Co-Chairs

Eric Van Cutsem, MD, PhD
Leuven Cancer Institute
University Hospitals Leuven
Leuven, Belgium

Philip Agop Philip, MD, PhD, FRCP
Wayne State University and Karmanos Cancer Institute
Detroit, Michigan, United States

Faculty

Maria Antonieta Bali, MD, PhD
Erasmus Hospital, Free University of Brussels
Brussels, Belgium

Christiane Bruns, MD, PhD
University of Cologne
Cologne, Germany

Stefano Cascinu, MD, PhD
University of Modena and Reggio Emilia
Modena, Italy

Gabriela Chiorean, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States

Volker Ellenrieder, MD, PhD
University Hospital Göttingen
Göttingen, Germany

Teresa Macarulla, MD, PhD
Vall d’Hebron University Hospital
Barcelona, Spain

Gerald Prager, MD
Medical University of Vienna
Vienna, Austria

Agenda

Friday, 29 September

19.00  Buffet dinner

19.30  Welcome, introduction, and warm-up quiz
       Eric Van Cutsem, MD, PhD, Philip Agop Philip, MD, PhD,
       FRCP, and prIME Oncology Medical Director

19.45  Setting the stage: Key milestones and challenges in
       the management of pancreatic cancer
       Eric Van Cutsem, MD, PhD

20.10  Audience questions and faculty panel commentary

20.15  Hot topic debate: Should every patient with resectable
       pancreatic cancer receive upfront chemotherapy?
       Yes: Christiane Bruns, MD, PhD
       No: Gabriela Chiorean, MD

20.45  Audience questions and faculty panel commentary

21.00  Concluding remarks

Saturday, 30 September

07.30  Breakfast

08.30  Introduction and objectives of day 2
       Eric Van Cutsem, MD, PhD, and Philip Agop Philip,
       MD, PhD, FRCP

08.35  Keynote Lecture 1—Advances in molecular biology of
       pancreatic cancer: Understanding genetic complexity
       and molecular heterogeneity
       Volker Ellenrieder, MD, PhD

09.00  Audience questions and faculty panel commentary

09.10  Imaging of pancreatic cancer: Current state of the art
       and future trends
       Maria Antonieta Bali, MD, PhD

09.35  Audience questions and faculty panel commentary

09.45  Case #1—Resectable pancreatic ductal carcinoma
       Christiane Bruns, MD, PhD (Part I), and Teresa Macarulla,
       MD, PhD (Parts II and III)

       Part I: Advances in surgery

10.40  Audience questions and faculty panel commentary

10.55  Coffee break

11.15  Case #2—Locally advanced unresectable pancreatic
       cancer: Evaluating treatment options
       Stefano Cascinu, MD, PhD

11.45  Audience questions and faculty panel commentary

12.00  Selecting the primary endpoint for neoadjuvant and
       adjuvant clinical trials
       Eric Van Cutsem, MD, PhD, and Faculty Panel

12.20  Keynote Lecture 2—Targeting the tumor
       microenvironment in pancreatic cancer
       Gabriela Chiorean, MD

12.45  Audience questions and faculty panel commentary

12.55  Lunch

13.55  Case #3—Metastatic pancreatic ductal
       adenocarcinoma: Selecting optimal first-line approach
       Philip Agop Philip, MD, PhD, FRCP

14.25  Audience questions and faculty comments

14.40  Case #4—Progressive pancreatic cancer: Optimal
       sequencing of systemic therapy?
       Gerald Prager, MD

15.10  Audience questions and faculty comments

15.25  Clinical opinion poll questions: Challenging the experts
       Faculty Panel

15.40  Pancreatic cancer management in the coming year:
       What can we expect?
       Philip Agop Philip, MD, PhD, FRCP

15.55  prIME Points™
       Eric Van Cutsem, MD, PhD

16.00  Adjourn
Target Audience

This educational activity is designed for European surgical, radiation, and medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

- Describe the genomic complexity and molecular heterogeneity of pancreatic cancer
- Explain advances in imaging modalities of pancreatic cancer and recognize imaging criteria defining resectability
- Identify multimodality treatment strategies for localized resectable, borderline, and unresectable pancreatic cancer
- Select the most appropriate therapeutic approach for metastatic pancreatic ductal adenocarcinoma based on patient and disease characteristics, both in the first-line setting and beyond
- Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of pancreatic cancer management
- Describe emerging treatment strategies in pancreatic cancer, including the role of immunotherapy

Support

This educational activity is supported by grants from Celgene and Shire.

Meeting Venue

Hilton Budapest
Hess András tér 1-3
Budapest, Hungary

Register

Apply for your travel grant!
For more information and to register, visit www.prIMEoncology.org/expert-practice-pancreatic-cancer-2017

Sunshine Act and EFPIA Disclosure Code

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Provider

This activity is provided by prIME Oncology.